for major histocompatibilty complex.Class I molecules.proc.Natl Acad Sci USA，1995，92，3081.        17  Philips JH，lanirrLL.Dessection of the lymphlcine-activated killed phenonmenon：relative contribution of peripheral blood natural killer cell and T lymphocytes to cytolysis. J EXP Med，1986：164，814.        18  Ortalao JR，Mason A，Overton R. Lymphckine-actived kill cells：analysis of progernitors and effectors. J Exp Med，1986，164：1193.        19  陆云，孔宪涛，仲人前，等. CD16细胞表达与NK活性的关系.中国免疫学杂志，1997，13(3)：177.        20  张峻梅，张正伟.肺癌患者细胞免疫的改变及临床意义.四川肿瘤防治，1999，12(3)：18-20.        21  Hangiri T，Tashino I，Takenoyama M，et al. Effects of  interleukin-12 on the induction of cytotoxic T lymphocytes from the regional lymph node lymphocytes of patients with lung adenocarcinoma. Jpn J  Cancer Res，1998，89(2)：192.        22  Morgan DA，Ruscetti FW，Gallo RG，et al.Selective in vitro growth of T-lymphocytes from  normal  bone  marrow. Science，1996，193：1007.        23  Hellstrom KE，Hellstrom I.Principles of twmor immunity：tumor antigens.In：Devita VT，Heliman S，Rosenberg SA.eds. Biologic therapy of cancer.Philadelphia JB  Lippincon，1991，35.        24  Mitchell M，Mitchell J，Kempf RA， et al.Active immunothe-raphy for melanoma：phase I trial of all ageneis lysates and a nevel adjunant. Cancer Res，1988：48，5888.        25  Osband ME，Ross S. Probliems in the investigastional study and clinical use of cancer immunotherapy. Immunol Today，1990，11(6)：193-195.

上一页  [1] [2] [3]